Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

EpiHope

Financiado

Cerrado

Epigenetic biomarkers for prediction of vascular complications and response to t...

Epigenetic biomarkers for prediction of vascular complications and response to treatment in subjects with diabetes Type 2 diabetes (T2D) is one of the leading causes of death through its deleterious effects on cardiovascular disease (CVD). The complications of T2D can be reduced through early and appropriate preventive and therapeutic interven... ver más

31/05/2018

LUNDS UNIVERSITET

174K€

Presupuesto del proyecto: 174K€

Líder del proyecto

LUNDS UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2018-05-31

MSCA-IF-2015-EF: Marie Skłodowska-Curie Individual F...

I+D

Cerrada hace 9 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

LUNDS UNIVERSITET

173.86K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

Proceed Pharmacoepigenetics for precision medicine in type 2 diabete... 150K€ Cerrado

IRGENOMICS Genetical genomics of type 2 diabetes and cardiovascular phe... 178K€ Cerrado

GEPIDIAB Genetics and epigenetics of Type 2 Diabetes physiology 2M€ Cerrado

EPI-MIGRANT Identification of epigenetic markers underlying increased ri... 4M€ Cerrado

T2DSystems Development of a systems biomedicine approach for risk ident... 6M€ Cerrado

PAINTBOX Pancreatic islet dysfunction and type 2 diabetes beyond th... 2M€ Cerrado

Duración del proyecto: 26 meses Fecha Inicio: 2016-03-31
Fecha Fin: 2018-05-31

Líder del proyecto

LUNDS UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 174K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Type 2 diabetes (T2D) is one of the leading causes of death through its deleterious effects on cardiovascular disease (CVD). The complications of T2D can be reduced through early and appropriate preventive and therapeutic interventions. Several studies suggest that epigenetics may play a key role in the pathogenesis of these diseases. However, additional studies are needed to improve primary prevention and treatment of T2D and vascular complications. Our overall objective is to identify novel epigenetic biomarkers of clinical relevance that predict, monitor progression and forecast response to treatment of T2D and CVD. First we aim to identify clinically useful epigenetic biomarkers (DNA methylation will be analysed genome-wide) that can predict the glycaemic response to metformin treatment and future risk of CVD in newly diagnosed T2D patients recruited from ANDIS cohort. Second, the most efficient epigenetic biomarkers identified will be validated in T2D patients from ANDIS using pyrosequencing. Third, we aim to make combined predictive risk scores with our novel epigenetic biomarkers, genetic and clinical risk factors to assess risk for CVD. Finally, we will test functional characterization of the validated epigenetic biomarkers in target tissues from T2D patients, and in vitro follow-up studies will be developed. This project represents an outstanding opportunity for personalized treatment for T2D, proposing for the first time pharmacoepigenetics in this field, and also for the development of a panel of high-quality epigenetic biomarkers together with combined risk scores, aiming to give a new reliable clinical tool for early prevention of CVD in T2D patients. Notably, epigenetic modifications can be manipulated more readily than genomic mutations, and thereby has much of potential for pharmacological applications. In summary, the findings of robust epigenetic biomarkers will optimize the therapeutics of T2D and the preventive care of vascular complications.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores